Cell technologies in the treatment of rheumatic diseases

Rheumatic diseases are caused by chronic autoimmune processes that require long-term therapy, which leads to the formation of resistance to the drugs used. The search for new approaches to their treatment in recent years has been enriched with the use of cell therapy methods. They are considered in...

Full description

Bibliographic Details
Main Authors: N. F. Soroka, M. P. Potapnev, N. A. Martusevich
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2019-12-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/2806
id doaj-54a4e39f974d44a684c9aaa36c39ac78
record_format Article
spelling doaj-54a4e39f974d44a684c9aaa36c39ac782021-08-02T09:05:53ZrusIMA-PRESS LLCНаучно-практическая ревматология1995-44841995-44922019-12-0157668569210.14412/1995-4484-2019-685-6922555Cell technologies in the treatment of rheumatic diseasesN. F. Soroka0M. P. Potapnev1N. A. Martusevich2Belarusian State Medical UniversityBelarusian State Medical University; Republican Research and Practical Center of Transfusiology and Medical BiotechnologiesBelarusian State Medical UniversityRheumatic diseases are caused by chronic autoimmune processes that require long-term therapy, which leads to the formation of resistance to the drugs used. The search for new approaches to their treatment in recent years has been enriched with the use of cell therapy methods. They are considered in this review of the literature and include the transplantation of hematopoietic stem cells, mesenchymal stem (stromal) cells, the induction or administration of T-regulatory cells, tolerogenic dendritic cells. The paper discusses methods of obtaining cell products, their safety and clinical use in patients with systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and other rheumatic diseases, and treatment complications. Based on the analysis, the authors give the comparative characteristics of various types of tolerogenic cell therapy for rheumatic diseases and point out their advantages, disadvantages, and the specific features of clinical application.https://rsp.mediar-press.net/rsp/article/view/2806rheumatic diseasescell producttolerogenic cell therapy
collection DOAJ
language Russian
format Article
sources DOAJ
author N. F. Soroka
M. P. Potapnev
N. A. Martusevich
spellingShingle N. F. Soroka
M. P. Potapnev
N. A. Martusevich
Cell technologies in the treatment of rheumatic diseases
Научно-практическая ревматология
rheumatic diseases
cell product
tolerogenic cell therapy
author_facet N. F. Soroka
M. P. Potapnev
N. A. Martusevich
author_sort N. F. Soroka
title Cell technologies in the treatment of rheumatic diseases
title_short Cell technologies in the treatment of rheumatic diseases
title_full Cell technologies in the treatment of rheumatic diseases
title_fullStr Cell technologies in the treatment of rheumatic diseases
title_full_unstemmed Cell technologies in the treatment of rheumatic diseases
title_sort cell technologies in the treatment of rheumatic diseases
publisher IMA-PRESS LLC
series Научно-практическая ревматология
issn 1995-4484
1995-4492
publishDate 2019-12-01
description Rheumatic diseases are caused by chronic autoimmune processes that require long-term therapy, which leads to the formation of resistance to the drugs used. The search for new approaches to their treatment in recent years has been enriched with the use of cell therapy methods. They are considered in this review of the literature and include the transplantation of hematopoietic stem cells, mesenchymal stem (stromal) cells, the induction or administration of T-regulatory cells, tolerogenic dendritic cells. The paper discusses methods of obtaining cell products, their safety and clinical use in patients with systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and other rheumatic diseases, and treatment complications. Based on the analysis, the authors give the comparative characteristics of various types of tolerogenic cell therapy for rheumatic diseases and point out their advantages, disadvantages, and the specific features of clinical application.
topic rheumatic diseases
cell product
tolerogenic cell therapy
url https://rsp.mediar-press.net/rsp/article/view/2806
work_keys_str_mv AT nfsoroka celltechnologiesinthetreatmentofrheumaticdiseases
AT mppotapnev celltechnologiesinthetreatmentofrheumaticdiseases
AT namartusevich celltechnologiesinthetreatmentofrheumaticdiseases
_version_ 1721235627258675200